ADMA Biologics, Inc.
ADMA
$16.54
-$0.04-0.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.55% | 6.46% | 27.19% | -75.96% | 211.61% |
| Total Depreciation and Amortization | 1.14% | -1.70% | 4.52% | 1.29% | 0.21% |
| Total Amortization of Deferred Charges | 15.88% | 6.25% | -15.79% | -13.24% | -13.10% |
| Total Other Non-Cash Items | -45.48% | 55.59% | -3.82% | 110.33% | -2,561.63% |
| Change in Net Operating Assets | 39.66% | -62.23% | 59.47% | -513.55% | 184.58% |
| Cash from Operations | 168.10% | -37.12% | 207.44% | -139.18% | 100.64% |
| Capital Expenditure | 92.46% | -493.23% | 48.48% | -70.51% | -161.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -452.63% | -371.43% | 116.67% |
| Cash from Investing | 98.08% | -468.58% | 46.46% | -71.64% | -150.46% |
| Total Debt Issued | -100.00% | 150.00% | -- | -- | -- |
| Total Debt Repaid | 99.38% | -151.56% | -- | -- | 0.00% |
| Issuance of Common Stock | 10.54% | -81.15% | 1,943.56% | -77.20% | -92.22% |
| Repurchase of Common Stock | 62.23% | -1,915.28% | 83.52% | -1,022.36% | 44.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.65% | -353.70% | -- | -- | -- |
| Cash from Financing | 67.23% | -58,068.75% | 100.67% | 77.03% | -21.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 190.81% | -254.88% | 159.20% | -291.74% | 1,169.62% |